Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

82.40 -1.34 (-1.60%)
Streaming Delayed Price Updated: 2:41 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 403,141
Open 83.49
Bid (Size) 82.28 (4)
Ask (Size) 82.40 (1)
Prev. Close 83.74
Today's Range 81.52 - 85.50
52wk Range 55.02 - 98.40
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Decoding 9 Analyst Evaluations For Axsome Therapeutics
Via Benzinga
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
These innovative drugmakers are hard to ignore. 
Via The Motley Fool

Performance

YTD
+6.93%
+6.93%
1 Month
+8.42%
+8.42%
3 Month
+18.20%
+18.20%
6 Month
-3.60%
-3.60%
1 Year
+11.10%
+11.10%

More News

Read More
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
Via InvestorPlace
Should You Buy This Sinking Stock on the Dip?
Via The Motley Fool
15 Analysts Assess Axsome Therapeutics: What You Need To Know
Via Benzinga
Why Axsome Therapeutics Stock Is Sinking Today
Via The Motley Fool
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
3 Monster Stocks in the Making You Can Buy Right Now
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
Via InvestorPlace
Prediction: These 2 Growth Stocks Could Triple By 2030
Via The Motley Fool
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.